DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS

Hafsah Nabi; R. Ibsen; Michael Ibsen; Jakob Kjellberg; Merete Lund Hetland; Bente Glintborg

doi:10.1136/annrheumdis-2023-eular.812

DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS

Hafsah Nabi, R. Ibsen, Michael Ibsen, Jakob Kjellberg, Merete Lund Hetland, Bente Glintborg

Department for Rheumatology and Spine Diseases

Original language	Danish
Publication date	2023
DOIs	https://doi.org/10.1136/annrheumdis-2023-eular.812
Publication status	Published - 2023
Event	EULAR 2023 - Milano, Italy Duration: 31 May 2023 → 2 Jun 2023

Conference

Conference	EULAR 2023
Country/Territory	Italy
City	Milano
Period	31/05/2023 → 02/06/2023

Access to Document

10.1136/annrheumdis-2023-eular.812

Cite this

Nabi, H., Ibsen, R., Ibsen, M., Kjellberg, J., Hetland, M. L., & Glintborg, B. (2023). DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS. Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441. Abstract from EULAR 2023, Milano, Italy. https://doi.org/10.1136/annrheumdis-2023-eular.812

DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS. / Nabi, Hafsah; Ibsen, R.; Ibsen, Michael et al.
2023. Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441 Abstract from EULAR 2023, Milano, Italy.

Research output: Contribution to conference › Conference abstract for conference › Research › peer-review

Nabi, H, Ibsen, R, Ibsen, M, Kjellberg, J, Hetland, ML & Glintborg, B 2023, 'DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS', EULAR 2023, Milano, Italy, 31/05/2023 - 02/06/2023 pp. Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441. https://doi.org/10.1136/annrheumdis-2023-eular.812

@conference{158776df3ed84f45bd273121566cad95,

title = "DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS",

author = "Hafsah Nabi and R. Ibsen and Michael Ibsen and Jakob Kjellberg and Hetland, {Merete Lund} and Bente Glintborg",

note = "COPECARE; EULAR 2023 ; Conference date: 31-05-2023 Through 02-06-2023",

year = "2023",

doi = "10.1136/annrheumdis-2023-eular.812",

language = "Dansk",

pages = "Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441",

}

TY - ABST

T1 - DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS

AU - Nabi, Hafsah

AU - Ibsen, R.

AU - Ibsen, Michael

AU - Kjellberg, Jakob

AU - Hetland, Merete Lund

AU - Glintborg, Bente

N1 - COPECARE

PY - 2023

Y1 - 2023

U2 - 10.1136/annrheumdis-2023-eular.812

DO - 10.1136/annrheumdis-2023-eular.812

M3 - Konferenceabstrakt til konference

SP - Annals of the rheumatic diseases, vol. 82, suppl. 1, page 441

T2 - EULAR 2023

Y2 - 31 May 2023 through 2 June 2023

ER -